<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01417169</url>
  </required_header>
  <id_info>
    <org_study_id>SNUCH-1102</org_study_id>
    <nct_id>NCT01417169</nct_id>
  </id_info>
  <brief_title>Micafungin Prevention Study for Invasive Fungal Disease in Pediatric &amp; Adolescent Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric &amp; Adolescent Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate safety and prophylaxis effect of micafungin after hematopoietic
      stem cell transplantation. Micafungin is administered until confirmation of neutrophil
      engraftment or treatment failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate absence of proven, probable, possible, suspected
      invasive fungal disease (IFDs) through the end of prophylaxis therapy and during 4 weeks
      after stopping of micafungin prophylaxis after Autologous hematopoietic stem cell
      transplantation in pediatric and adolescent neutropenia patients. Patients will receive
      micafungin until the earliest of the following: 1) neutrophil engraftment; 2) development of
      proven, provable, possible or suspected invasive fungal disease; 3) development of
      unacceptable drug toxicity; 4) withdrawal from study participation or discontinuation of
      study treatment. Safety profile of micafungin is also evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence rate of IFDs assessed by physical examination and serum galactomannan test</measure>
    <time_frame>4 weeks</time_frame>
    <description>Absence of proven, probable, possible invasive fungal disease (IFDs) through the end of prophylaxis therapy and during 4 weeks after stopping of Micafungin prophyalxis after HSCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>100 days</time_frame>
    <description>IFD-related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by lab-test and adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>Safety profiles</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Neutropenia</condition>
  <condition>Fungal Disease</condition>
  <arm_group>
    <arm_group_label>Micafungin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>micafungin</intervention_name>
    <description>Eligible patients who provided informed consent form will be administered micafungin at 50 mg/day (1mg/kg/day for patients weighting &lt;50kg) as 1-h infusion. Infusion of Micafungin will be started on the day -2 of the conditioning course of autologous stem cell transplantation</description>
    <arm_group_label>Micafungin</arm_group_label>
    <other_name>Micafungin sodium</other_name>
    <other_name>Mycamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients will receive autologous hematopoietic stem cell transplantation including 2nd
             autologous transplantation

          2. Under 21 years old, pediatric, adolescent patients.

        Exclusion Criteria:

          1. Aspartate transaminase or alanine transaminase level &gt; 5 times UNL

          2. Bilirubin &gt; 2.5 times UNL

          3. History of allergy, sensitivity, or any serious reaction to an echinocandin

          4. Invasive fungal disease at the time of enrolment

          5. Systemic antifungal therapy within 72 hrs before administration of the first dose of
             study drug

          6. Positive pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung Jin Kang, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyoung Jin Kang, M.D, Ph.D</last_name>
    <phone>82 2 2072 3304</phone>
    <email>kanghj@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyery Kim, M.D.</last_name>
    <phone>82 2 2072 0177</phone>
    <email>taban@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Chongno-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoung Jin Kang, M.D, Ph.D</last_name>
      <phone>82 2 2072 3304</phone>
      <email>kanghj@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2011</study_first_submitted>
  <study_first_submitted_qc>August 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2011</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Micafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

